Item 7.01. Regulation FD Disclosure.
On May 9, 2022, Lucid Diagnostics Inc. (the "Company") announced that its
wholly-owned CLIA-certified and CAP-accredited laboratory, LucidDx Labs Inc.,
has entered into a participating provider agreement with MediNcrease Health
Plans, LLC, a national, directly-contracted, multi-specialty PPO provider
network with over 8 million lives covered through its clients and payers, which
include regional and national health plans, insurance companies, third party
administrators, self-insured employer groups, municipalities, unions and other
entities involved in the management of medical claims. A copy of the press
release is attached to this report as Exhibit 99.1 and is incorporated herein by
reference.
The information furnished under this Item 7.01, including the exhibit related
thereto, shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, nor shall it be deemed incorporated by
reference in any disclosure document of the Company, except as shall be
expressly set forth by specific reference in such document.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No. Description
99.1 Press release.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
© Edgar Online, source Glimpses